Geneva/Oslo/New York, 3 February 2021 — The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance and the World Health Organisation, as co-leads of the COVAX initiative for equitable global access to COVID-19 vaccines, alongside key delivery partner UNICEF, are pleased to publish COVAX's first interim distribution forecast.
Building on the publication of the 2021 COVAX global and regional supply forecast, the interim distribution forecast provides information on early projected availability of doses of the Pfizer/BioNTech vaccine in Q1 2021 and the AstraZeneca/Oxford vaccine candidate in first half 2021 to COVAX Facility participants. This announcement comes less than two weeks after the announcement of the signed advance purchase agreement with Pfizer/BioNTech and a little more than a month after the first COVID-19 vaccine received WHO EU approval.
The purpose of sharing the interim distribution with countries, even in today's highly dynamic global supply environment, is to provide governments and health systems with the information they need to plan for their national vaccination programmes. Final allocations will be published in due course.
The interim distribution forecast outlines projected delivery of vaccine doses to all Facility participants, with the exception of participants who have either exercised their rights to opt-out, have not submitted vaccine requests, or have not yet been allocated doses.
The interim distribution forecast is available here.
Notes to editors
The latest COVAX global supply forecast is always available here.
The latest list of COVAX Facility participants is always available here.
Media Contacts
Meg Sharafudeen, Gavi
+41 79 711 5554
[email protected]
Iryna Mazur, Gavi
+41 79 429 3671
[email protected]
Evan O'Connell, Gavi
+33 6 17 57 21 26
[email protected]
CEPI Press Office
+44 7387 055214
[email protected]
WHO Press Office
[email protected]
Sabrina Sidhu, UNICEF New York
+1 917 476 1537
[email protected]
Anne Sophie Bonefeld, UNICEF Copenhagen
+45 2469 4676
[email protected]
Image Credit: Gavi/ MIKO
CEPI statement: CEO welcomes Emergency Use Listing for NVX-CoV2373
CEPI and Clover expand partnership for COVID-19 vaccine to include evaluation as a booster
